ShockWave Medical (SWAV)
(Delayed Data from NSDQ)
$328.54 USD
-0.22 (-0.07%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $329.29 +0.75 (0.23%) 7:24 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$328.54 USD
-0.22 (-0.07%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $329.29 +0.75 (0.23%) 7:24 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Zacks News
Shockwave Medical (SWAV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Shockwave Medical (SWAV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat Likely for DENTSPLY SIRONA (XRAY) in Q3 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) third-quarter 2023 results are likely to reflect a recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.
Baxter (BAX) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Baxter's (BAX) third-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) third-quarter results are likely to reflect continued segmental strength.
Wall Street Analysts See a 27.54% Upside in Shockwave Medical (SWAV): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Shockwave Medical (SWAV) points to a 27.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Integer (ITGR) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 20.95% and 8.71%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
NextGen (NXGN) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
NextGen's (NXGN) second-quarter fiscal 2024 results reflect strength in its Recurring revenues.
Shockwave Medical (SWAV) Announces IVL Studies' Positive Results
by Zacks Equity Research
Shockwave Medical's (SWAV) latest announcement of two new publications validates the utility of IVL in complex nodular and eccentric calcium.
Are Options Traders Betting on a Big Move in Shockwave Medical (SWAV) Stock?
by Zacks Equity Research
Investors need to pay close attention to Shockwave Medical (SWAV) stock based on the movements in the options market lately.
Should Vanguard Russell 2000 ETF (VTWO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VTWO
Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VTWG
Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSMD
Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JSMD
3 Intriguing Stocks to Buy After Earnings
by Shaun Pruitt
With various scenarios, these top-rated stocks are appealing after reporting their Q2 results on Monday and should have more upside as we progress through 2023.
Shockwave Medical (SWAV) Q2 Earnings Miss, Revenues Surge Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) second-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
Shockwave Medical (SWAV) Misses Q2 Earnings Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of -12.64% and 3.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWO
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSMD
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Implied Volatility Surging for ShockWave Medical (SWAV) Stock Options
by Zacks Equity Research
Investors need to pay close attention to ShockWave Medical (SWAV) stock based on the movements in the options market lately.
Should Invesco S&P MidCap 400 Equal Weight ETF (EWMC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for EWMC
Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JSMD
Is Invesco S&P MidCap 400 Equal Weight ETF (EWMC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EWMC
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.